Proof of efficacy, maintenance of efficacy, long-term safety and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in a multicenter study in the treatment of patients with chronic non-specific low back pai

Phase 1

• Conditions: For the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.; Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

• Registration Number: EUCTR2020-000107-36-AT
• Lead Sponsor: Vertanical GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-13
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 808

Inclusion Criteria

1. Male and female patients (18 years and older)
2. Chronic (for at least three months) non-specific pain in the lower back (between the lower ribcage and the gluteal folds)
3. Pain intensity on average at least 4 points on an 11-point NRS (one month before the start of the study)
4. Patients with indicated drug treatment* where previous optimised treatments** with non-opioid analgesics have not led to sufficient pain relief or
were unsuitable due to contraindications or intolerance.
* Drug treatment is indicated if analgesic drug therapy is considered supportive for the realisation of activating measures, or if the patient has
unbearable functional disabilities as a result of the pain, despite regularly performing these measures.
** Treatment is considered optimised when
I. a further increased drug dose is unsuitable from a medical perspective considering side effects and/or
II. it is not expected that a higher drug dose would result in a further advantage in terms of efficacy.
5. Willingness of both men and women to use a reliable method of contraception during study participation and for three months after taking the last
dose of the IMP
6. Signed patient information and informed consent form
7. Understanding of the English language, ability to give consent and compliance
8. The patient has understood the instructions to avoid changes in lifestyle and dietary habits
9. The patient has understood the principle of the patient diary and gives their consent to keep it as instructed
Additional for Phase A
a1. The average value of the pain intensity in the morning of the 7 days before visit A2 (study week -1) must be at least 4 points on an 11-point NRS.
The last 7 entries of the pain intensity before visit A2 in the patient diary are used for the calculation (there must be at least 5 pain intensity
readings in the morning from the study week -1)
a2. Willingness not to take any analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) during participation in study
Phase A (except rescue medication)
a3. Willingness to continue a current non-drug therapy unchanged as planned during participation in Phase A
Additional for Phase B
b1. Previous and complete participation in Phase A until and including Visit A6
b2. Patient wishes to participate voluntarily in the long-term study
b3. From the investigator's point of view, further participation is considered medically safe
b4. Willingness not to take any additional analgesic medication (nonopioid and opioid analgesics as well as adjuvant analgesics) during the last two
weeks of study Phase B (except rescue medication).
Additional for Phase C
c1. Previous and complete participation in Phase B until and including Visit B10
c2. Patient wishes to participate voluntarily in the long-term study
c3. From the investigator's point of view, further participation is considered medically safe
Additional for Phase D
d1. Previous and complete participation in Phase B until and including Visit B10
d2. Patient has experienced a morning pain score improvement of at least 30% in treatment Phase B (mean morning pain score of study Week 43
compared to the mean morning pain score in the 7 days prior to visit A2 (study week -1), there must be at least four values from study Week 43
and five values from study week -1)
d3. Patient wishes to participate voluntarily in the study
d4. From the investigator's point of v

Exclusion Criteria

1. Professional groups for which the ability to operate machinery and drive vehicles is the primary activity (including truck, bus and forklift drivers,
pilots)
2. Alcohol/drug/medication abuse and previous or current intake of methadone in the patient's medical history or suspected by the investigator
3. Intake of analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) within seven days prior to the start of the study
4. Taking cannabis-based medicinal products within 30 days prior to the start of the study
5. HIV, dementia (which impairs the assessment of symptoms)
6. Severe forms of the following diseases: Anaemia, hematological/autoimmune/endocrinal/renal/hepatic/respiratory/cardiovascular or
gastrointestinal diseases, symptomatic peripheral vascular diseases
7. Cardiovascular event in the past three months, poorly managed high blood pressure, untreated hypothyroidism, patients with Crigler-Najjar
syndrome or Rotor syndrome, surgery within the past two months
8. Severe mental illnesses (e.g., psychosis, schizophrenia, bipolar disorder) currently or in the past, severe depression not due to chronic low back pain
currently or in the past, or individuals at risk of suicide (examined using the MINI questionnaire: when at least one module is fulfilled)
9. Severe mental illness (psychosis, schizophrenia, bipolar disorder, severe depression, anxiety disorder) currently or in the past in a firstdegree relative
(parents and children); suicide in a first-degree relative (parents and children)
10. Patients with an active cancer or tumor-related pain or severe pain due to physical injury
11. Other painful comorbidities, excluding low back pain, that could interfere with the patient's evaluation during the study or the assessment of pain
12. Well-known strong adverse events in connection with cannabis consumption before the start of the study
13. Known allergy to cannabis and/or sesame seeds and products derived from them
14. Known hypersensitivity to the ingredients of the rescue medication
15. Planned blood donation, planned sperm or egg donation, planned freezing of eggs or sperm
16. Pregnancy, breastfeeding, desire to have children (within the next 20 months)
17. Participation in another clinical interventional trial within the past 30 days before the start of the study
18. Inability to give consent, care dependency, patient has a legal guardian/caregiver, or is immobile
19. The patient is in need of special protection (e.g., incarcerated; institutionalized by a court or judicial authority; in a dependent or
employment relationship with the sponsor, an external service provider of the sponsor (who is involved in the study conduct), the investigator, or the
study site).
Additional for Phase A:
a1. In the case of a current non-drug therapy (e.g. physical or behavioural therapy, acupuncture, massage, thermotherapy), which significantly
modulates the perception of pain, it was not maintained unchanged for at least eight weeks prior to study participation in Phase A.
Additional for Phase D
d1. Intake of additional analgesic medication (non-opioid and opioid analgesics as well as adjuvant analgesics) within 21 days prior to the start of study
Phase D (except rescue medication).
d2. In the case of a current non-drug therapy (e.g. physical or behavioural therapy, acupuncture, massage, thermotherapy) that significantly modulates
the perception of pain, it was not maintaine

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified